Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Novartis AG is a global biopharmaceutical company focused on the research, development, manufacture, and commercialization of innovative prescription medicines. The company operates primarily within the pharmaceuticals and life sciences industry, with an emphasis on patented therapies that address serious and chronic diseases. Its core revenue is driven by branded innovative medicines across therapeutic areas including cardiovascular, immunology, neuroscience, oncology, ophthalmology, and rare diseases.
Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has evolved through portfolio restructuring and divestitures to sharpen its focus on innovative medicines. A significant milestone in this evolution was the 2023 spin-off of Sandoz Group AG, its former generics and biosimilars division, resulting in Novartis becoming a pure-play innovative medicines company. The company positions itself around science-led innovation, advanced development platforms, and global scale in research and commercialization.
Business Operations
Novartis operates through a single reportable business segment, Innovative Medicines, which encompasses all pharmaceutical research, development, manufacturing, and commercial activities. Revenue is primarily generated from patented therapies, with key products including treatments for heart failure, multiple sclerosis, psoriasis, cancer, and retinal diseases. The company maintains extensive internal capabilities across drug discovery, clinical development, biologics manufacturing, and global supply chains.
Operations are supported by a network of wholly owned subsidiaries and research centers, including Novartis Institutes for BioMedical Research (NIBR), which serves as the company’s global drug discovery organization. Novartis also maintains strategic collaborations with biotechnology firms, academic institutions, and technology partners to advance novel therapies and digital health-enabled development processes. Commercial operations span both direct sales and distributor-based models depending on market structure.
Strategic Position & Investments
Novartis’s strategic direction centers on high-value innovative medicines, therapeutic area leadership, and operational efficiency. The company has prioritized investment in cardiovascular, immunology, neuroscience, and oncology pipelines, while exiting non-core or lower-margin businesses. Capital allocation emphasizes internal R&D, selective bolt-on acquisitions, and external innovation partnerships rather than large-scale diversified expansion.
Recent strategic actions include targeted acquisitions of early- and mid-stage biotechnology companies to strengthen the clinical pipeline, as well as continued investment in gene and cell therapies, radioligand therapies, and advanced biologics manufacturing. Novartis also invests in digital technologies and data science to improve clinical trial execution, regulatory submissions, and commercial engagement, positioning the company competitively among global pharmaceutical peers.
Geographic Footprint
Novartis is headquartered in Basel, Switzerland, and operates in more than 140 countries worldwide. Its largest markets include North America, Europe, and Asia-Pacific, with the United States representing the single largest source of revenue. The company maintains major research and development hubs in Switzerland and the United States, complemented by manufacturing sites across Europe, North America, and Asia.
Internationally, Novartis has a strong presence in emerging markets, including China, Japan, Latin America, and parts of Africa and the Middle East, where it combines innovative medicines with access and affordability programs. This broad geographic reach supports diversified revenue streams and global clinical development capabilities.
Leadership & Governance
Novartis is led by an executive team with a stated focus on scientific excellence, ethical governance, and long-term value creation for patients and shareholders. The leadership emphasizes a culture of innovation, accountability, and disciplined capital allocation aligned with the company’s strategic transformation into a pure innovative medicines organization.
Key executives include:
- Vasant (Vas) Narasimhan – Chief Executive Officer
- Harry Kirsch – Chief Financial Officer
- Marie-France Tschudin – President, Innovative Medicines US
- Shreeram Aradhye – Chief Medical Officer
- Fiona Marshall – President, Biomedical Research, Novartis Institutes for BioMedical Research
- Laila Khouri – Chief People & Organization Officer
The Board of Directors oversees corporate governance, risk management, and executive compensation, with governance practices aligned to Swiss regulatory standards and international best practices for publicly listed life sciences companies.